Home » Topics » Endocrine/metabolic, BioWorld Science

Endocrine/metabolic, BioWorld Science
RSS

NO-1886 in phase II clinical trials

June 7, 1996

Sankyo discovers ACAT inhibitor

June 7, 1996

Hoescht reports imidobisphosphonic acid derivatives

June 7, 1996

Fujisawa claims ACAT inhibitors

June 7, 1996

Completion of phase I clinical trials on human red blood cell substitute

May 31, 1996

Celtrix announces the initiation of two phase I trials of SomatoKine

May 31, 1996

ACAT inhibitors from Warner-Lambert

May 31, 1996

Multicenter clinical trial indicates alendronate effective in osteoporotic fracture prevention

May 31, 1996

PKC pathway activation may have therapeutic significance in bone disease management

May 31, 1996

New contraceptives reported by Akzo Nobel

May 24, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...